List of Excipients in Branded Drug IMBRUVICA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacyclics LLC	IMBRUVICA	ibrutinib	57962-070	CROSCARMELLOSE SODIUM
Pharmacyclics LLC	IMBRUVICA	ibrutinib	57962-070	FERRIC OXIDE YELLOW
Pharmacyclics LLC	IMBRUVICA	ibrutinib	57962-070	GELATIN
Pharmacyclics LLC	IMBRUVICA	ibrutinib	57962-070	TITANIUM DIOXIDE

IMBRUVICA Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 9, 2026

IMBRUVICA (ibrutinib) has a mature oral solid-dose franchise with expanding formulation requirements across chronic hematologic cancers. The strongest excipient opportunities are in pediatric and dysphagia-friendly delivery, taste masking, suspension stability, global supply resilience, and differentiated generic formulations. The commercial market remains substantial, but compound-patent protection and formulation-related rights make launch timing and freedom-to-operate analysis critical.

What is IMBRUVICA and how is it formulated?

IMBRUVICA is a covalent Bruton’s tyrosine kinase inhibitor marketed by AbbVie and Janssen Biotech. The FDA approved ibrutinib in 2013 for mantle cell lymphoma and later expanded its use to chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, and chronic graft-versus-host disease. It is administered orally as capsules, tablets, and an oral suspension in the United States.[1]

IMBRUVICA dosage forms

Dosage form	Commercial strengths	Primary commercial use
Capsules	70 mg, 140 mg	Initial and continuing adult therapy
Tablets	140 mg, 280 mg, 420 mg, 560 mg	Adult dosing and regimen flexibility
Oral suspension	70 mg/mL	Pediatric patients and patients unable to swallow solid dosage forms

The recommended dose varies by indication. Adult regimens generally range from 420 mg to 560 mg once daily. Pediatric chronic graft-versus-host disease dosing is based on body surface area and requires a liquid formulation for many patients.[1]

What excipients are used in IMBRUVICA capsules?

The capsule formulation uses a conventional immediate-release excipient platform. FDA labeling identifies croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate in the capsule fill. The capsule shell contains gelatin and titanium dioxide, with printing ink components.[1]

This platform indicates that the capsule depends on:

• Microcrystalline cellulose for bulk and powder compactability.
• Croscarmellose sodium for rapid disintegration.
• Sodium lauryl sulfate for wetting and dispersion of the poorly water-soluble active ingredient.
• Magnesium stearate for lubrication during capsule filling.

The strategy is technically conservative and suitable for high-volume manufacturing. It also creates potential generic differentiation through lower-surfactant systems, improved dissolution robustness, and excipient substitutions that reduce sensitivity to raw-material variability.

What excipients are used in IMBRUVICA tablets?

The tablet formulation uses a broader blend that includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and sodium lauryl sulfate. The film coating includes standard coating polymers, plasticizers, opacifiers, and pigments.[1]

The tablet formulation creates more formulation variables than the capsule:

• Lactose and microcrystalline cellulose control tablet mass and compression.
• Povidone supports granulation or binding.
• Croscarmellose sodium controls breakup after ingestion.
• Sodium lauryl sulfate supports wetting and dissolution.
• Film coating protects the core, controls appearance, and supports product identification.

The presence of multiple strengths creates scale-up and content-uniformity requirements. A generic manufacturer may prefer a common blend across strengths, but high-dose tablets may require different compression settings, tablet dimensions, or coating weight.

What commercial opportunities exist for IMBRUVICA excipients?

The highest-value opportunities are linked to patient access and lifecycle management rather than simple substitution of commodity ingredients.

1. Pediatric and dysphagia-friendly delivery

The oral suspension creates demand for excipients that support:

• Physical stability during storage.
• Rapid redispersion after shaking.
• Accurate dosing at low volumes.
• Acceptable taste and mouthfeel.
• Microbiological control.
• Compatibility with oral syringes and dosing adapters.

Suspension excipient suppliers can compete through polymeric suspending agents, wetting agents, sweeteners, flavor systems, and preservative-free stabilization approaches. A supplier that can provide a complete, validated platform has greater commercial value than one selling an isolated commodity ingredient.

2. Taste masking

Ibrutinib has a strong active pharmaceutical ingredient taste profile that can limit pediatric acceptance. Taste masking can use:

• Ion-exchange resins.
• Polymer-coated drug particles.
• Lipid or wax matrices.
• Cyclodextrin complexes.
• Multiparticulate systems.
• Flavor and sweetener combinations.

Taste masking must preserve dissolution and dose uniformity. A coating that delays release or reduces exposure may create regulatory and clinical equivalence problems. The most defensible opportunity is a taste-masking system that demonstrates rapid release under adult and pediatric dissolution conditions.

3. Excipient systems for poorly soluble drugs

Ibrutinib has low aqueous solubility. Sodium lauryl sulfate in the marketed solid dosage forms reflects the need for improved wetting and dispersion.[1] Generic developers may evaluate:

• Poloxamers.
• Sodium dodecyl sulfate alternatives.
• Soluplus-type polymers.
• Copovidone.
• Hydroxypropyl cellulose.
• Amorphous solid dispersions.
• Lipid-based self-emulsifying systems.

The commercial objective is not necessarily to increase absolute solubility. It is to achieve consistent dissolution without introducing food-effect, precipitation, stability, or manufacturing problems.

4. Excipient supply-chain resilience

IMBRUVICA is a high-value chronic therapy. A disruption involving microcrystalline cellulose, croscarmellose sodium, magnesium stearate, lactose, or film-coating materials can affect product continuity. Contract manufacturers and generic sponsors can create value through:

• Dual sourcing.
• Regional qualification of excipient suppliers.
• Alternate grades with equivalent functionality.
• Reduced reliance on a single coating system.
• Prequalified excipient kits for multiple strengths.

Suppliers with pharmaceutical-grade documentation, global regulatory support, and change-control discipline have an advantage over lower-cost commodity suppliers.

What formulation patents protect IMBRUVICA?

The principal exclusivity position has historically been based on the ibrutinib compound patent, supported by additional patents and regulatory exclusivities. Formulation, crystalline-form, dosage-form, and method-of-use rights may create separate barriers depending on jurisdiction and the active Orange Book listing.

Key U.S. patent position

Patent	Subject matter	Reported expiration profile
US 8,008,309	Ibrutinib compound and related pharmaceutical use	Patent-term-adjusted expiration reported in 2032
Related U.S. patents	Formulation, solid-state, use, or dosing claims	Expirations vary by patent and listing

US Patent No. 8,008,309 is widely associated with the core ibrutinib patent estate and has been reported with patent-term adjustment extending into 2032.[2] The exact enforceable scope depends on claim construction, terminal disclaimers, patent-term adjustment, pediatric extensions, and the relevant product listing.

Excipient strategy can intersect with patent risk where claims cover:

• Specific pharmaceutical compositions.
• Particle size or crystalline forms.
• Solid dispersions.
• Oral liquid formulations.
• Stabilized suspensions.
• Dosing regimens.
• Combination treatment methods.

A formulation that changes only inactive ingredients may still infringe a composition claim if the claim is drafted broadly. Conversely, a formulation may avoid a narrow excipient claim while remaining within a broader compound or method patent.

When does IMBRUVICA lose exclusivity?

The commercial loss-of-exclusivity date depends on the patent claim being asserted, the dosage form, the indication, and the outcome of Paragraph IV litigation or settlement agreements. The core ibrutinib patent estate has been reported to extend into 2032 in the United States, making immediate generic substitution unlikely while enforceable compound claims remain in force.[2]

Exclusivity timeline

Event	Date	Commercial effect
First FDA approval	2013	Launch of initial ibrutinib indications
Expanded CLL/SLL approval	2014	Rapid expansion of addressable market
First tablet approval	2017	Improved dose flexibility
Pediatric oral suspension approval	2022	Broader pediatric and swallowing-challenged use
Core patent expiration profile	Reported 2032	Principal U.S. generic-entry barrier
Post-expiration market	After enforceable patents expire	Potential multi-source generic competition

FDA regulatory exclusivity periods were shorter than the patent term. Orphan-drug exclusivity protected specific indications for seven years from approval, but it did not prevent approval of all ibrutinib products for unrelated indications or necessarily extend the core compound patent.[3]

What is the Orange Book status of IMBRUVICA?

IMBRUVICA is an FDA-approved small-molecule product with Orange Book-listed patent information. The Orange Book is relevant to abbreviated new drug applications because listed patents can generate Paragraph IV certification obligations and statutory litigation protections.[4]

For a generic applicant, the key questions are:

1. Which patents are currently listed against each reference-listed drug?
2. Do the listings cover capsules, tablets, suspension, or all approved forms?
3. Are the patents composition, method-of-use, or formulation patents?
4. Which claims expire first?
5. Has a 30-month stay been triggered by a Paragraph IV notice?
6. Does the applicant seek approval for all indications or carve out patented uses?

A generic sponsor can reduce risk through a section viii statement that omits a patented method of use, provided the labeling and marketing conduct do not induce infringement. This approach is more feasible where nonprotected indications represent a commercially meaningful share of demand.

Which companies are challenging IMBRUVICA exclusivity?

Generic companies that enter the ibrutinib market are likely to include major U.S. and international generic manufacturers with oncology capabilities. Public Paragraph IV activity must be assessed against current FDA Orange Book listings, Abbreviated New Drug Application filings, district-court complaints, and settlement agreements.

Potential competitive groups include:

• Large Indian generic manufacturers.
• U.S. generic companies with oncology portfolios.
• European manufacturers pursuing decentralized or national approvals.
• Specialty pharmaceutical companies using differentiated oral liquids or pediatric products.
• Authorized-generic or settlement-linked manufacturers.

The main competitive advantage will not come from the active ingredient alone. It will come from launch timing, manufacturing scale, API sourcing, regulatory readiness, and the ability to offer all major strengths without infringing formulation or method-of-use claims.

What generic entry risks exist for IMBRUVICA?

Generic entry risk is concentrated in four areas.

Patent litigation

A Paragraph IV filing can trigger patent litigation and a 30-month FDA approval stay under the Hatch-Waxman framework.[5] Litigation may focus on:

• Validity of the core compound patent.
• Obviousness of ibrutinib compounds or salts.
• Written description and enablement.
• Patent-term calculation.
• Infringement by a proposed formulation.
• Method-of-use labeling and induced infringement.

Bioequivalence

Ibrutinib generics must demonstrate bioequivalence to the relevant reference product. Formulation changes involving surfactants, particle size, solid-state form, or precipitation inhibitors may alter exposure. A conventional immediate-release formulation is easier to develop than a liquid product with taste-masking or suspension technology.

Indication carve-outs

IMBRUVICA has multiple indications with different clinical and patent histories. A carve-out strategy can accelerate approval but may limit sales if protected indications account for a major share of prescriptions.

Manufacturing and API barriers

Ibrutinib synthesis involves multiple chemical steps and requires control of impurities, solid-state properties, and residual solvents. The drug's high value makes API sourcing attractive, but oncology-grade manufacturing, regulatory inspection readiness, and reliable supply remain barriers.

How strong is the IMBRUVICA patent estate?

The estate is commercially strong while core compound protection remains enforceable. Its strength derives from the value of the active ingredient, the number of approved indications, the product's high revenue base, and the possibility of layered use and formulation rights.

Its relative weaknesses are typical of mature small-molecule estates:

• Compound claims face validity challenges as patent age increases.
• Several indications may be subject to different patent positions.
• Generic sponsors can use formulation design-around strategies.
• Section viii labeling may reduce method-of-use exposure.
• Multiple manufacturers can enter rapidly after the principal barrier expires.

The highest-risk period for the originator is the first 12 to 24 months after the earliest successful generic launch. Price erosion is likely to accelerate as additional suppliers enter.

How does IMBRUVICA compare with competing BTK inhibitors?

Product	Active ingredient	Formulation position	Competitive implication
IMBRUVICA	Ibrutinib	Capsules, tablets, oral suspension	Broad indication base and established brand
Calquence	Acalabrutinib	Capsules and tablets	Competes on selectivity and tolerability
BRUKINSA	Zanubrutinib	Capsules and tablets	Competes in CLL, MCL, and other B-cell malignancies
Jaypirca	Pirtobrutinib	Tablets	Noncovalent BTK inhibitor for resistant disease

Second-generation BTK inhibitors reduce the commercial certainty of post-expiration IMBRUVICA demand. Payer controls, physician switching, adverse-event profiles, and treatment sequencing may limit the volume available to ibrutinib generics. This makes pediatric liquid products, lower-cost global formulations, and supply reliability important differentiation strategies.[6]

What licensing and partnership opportunities exist?

Excipient and formulation companies can pursue four licensing models:

1. License a pediatric oral suspension platform to an originator or specialty partner.
2. Supply a proprietary taste-masking or suspension system to a generic sponsor.
3. License a solid-dispersion technology for improved dissolution.
4. Provide a qualified dual-source excipient platform to a contract development and manufacturing organization.

The most attractive deal structure is likely a formulation-plus-supply agreement. It can combine upfront technology fees, development milestones, commercial royalties, and long-term excipient supply. A purely commodity supply contract has lower margins and less protection from substitution.

What is the revenue exposure associated with IMBRUVICA?

IMBRUVICA generated approximately $5 billion in combined annual sales for AbbVie and Janssen in the early 2020s, although reported figures differ by company, geography, accounting treatment, and intercompany arrangements.[7,8] The product remains a major hematology asset despite competition from newer BTK inhibitors.

Revenue exposure for the originator includes:

• Direct sales erosion after generic entry.
• Price reductions in tender-driven markets.
• Switching to newer BTK inhibitors.
• Loss of high-volume adult indications.
• Continued protected demand in pediatric and selected specialty uses.

For excipient suppliers, the opportunity is smaller than the finished-product market but can remain durable because multiple generic manufacturers may need qualified materials for tablets, capsules, and oral liquids.

Key Takeaways

• IMBRUVICA uses conventional immediate-release excipients in capsules and tablets, with sodium lauryl sulfate supporting wetting and dissolution.
• The oral suspension creates the clearest opportunity for specialty excipient suppliers.
• Taste masking, suspension stability, pediatric dosing, and supply-chain resilience are commercially relevant development targets.
• US Patent No. 8,008,309 is associated with core ibrutinib protection and has been reported to expire in 2032 after patent-term adjustment.
• Generic entry will depend on Paragraph IV litigation, Orange Book listings, indication carve-outs, and formulation design-around strategies.
• The strongest commercial model is a proprietary excipient platform linked to long-term supply and regulatory support.
• Newer BTK inhibitors increase post-loss-of-exclusivity pressure and may reduce the addressable market for ibrutinib generics.

FAQs

Can a generic IMBRUVICA use different excipients?

Yes. A generic applicant can use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling. The alternative formulation must also avoid infringement of applicable formulation and composition claims.

Is IMBRUVICA oral suspension a major excipient opportunity?

Yes. The suspension requires specialized control of taste, sedimentation, redispersion, dose uniformity, microbiological quality, and syringe compatibility. These requirements create greater differentiation than the tablet or capsule platform.

Which excipient is most important for IMBRUVICA dissolution?

Sodium lauryl sulfate is a key wetting and dissolution-support excipient identified in the marketed capsule and tablet formulations. Generic developers may replace it, but the substitute must preserve dissolution and exposure across relevant conditions.

Can a company launch an ibrutinib generic before 2032?

Potentially, if it obtains a favorable litigation outcome, reaches a settlement with the patent holder, relies on a patent challenge, or receives approval under a strategy that avoids enforceable claims. Commercial launch timing depends on the specific patent claims and agreement terms.

Are biosimilar rules relevant to IMBRUVICA?

No. Ibrutinib is a chemically synthesized small molecule, so the primary U.S. pathway is the ANDA generic pathway rather than the biosimilar pathway under the Public Health Service Act. Biosimilar competition is relevant to biologic hematology products, not to IMBRUVICA itself.

References

1. U.S. Food and Drug Administration. (2024). IMBRUVICA (ibrutinib) prescribing information.
2. U.S. Patent and Trademark Office. (2011). U.S. Patent No. 8,008,309, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyridin-1-yl]piperidin-1-yl]prop-2-en-1-one.
3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355.
6. U.S. Food and Drug Administration. (2024). CALQUENCE, BRUKINSA, and JAYPIRCA prescribing information.
7. AbbVie Inc. (2024). Annual report for the year ended December 31, 2023.
8. Johnson & Johnson. (2024). Annual report for the year ended December 31, 2023.